Treating Restless Legs Syndrome: What the Latest Guidelines Recommend

A Major Shift in How RLS Is Treated

In 2025, the American Academy of Sleep Medicine (AASM) published updated clinical practice guidelines for the treatment of restless legs syndrome (RLS) and periodic limb movement disorder (PLMD). These guidelines represent a significant paradigm shift from previous recommendations published in 2012.

The most notable change: dopamine agonists are no longer recommended as standard first-line therapy due to the significant risk of a complication called augmentation. Instead, the guidelines now prioritize iron therapy and alpha-2-delta ligand medications (gabapentin, pregabalin).

This article explains the current recommended treatment approach based on these latest guidelines.

Step 1: Check and Treat Iron Deficiency

Iron assessment is now considered the first and most essential step in treating RLS, regardless of symptom severity.

Why Iron Matters

Iron is critical for dopamine production in the brain. Research consistently shows that many RLS patients have insufficient iron in specific brain regions, even when standard blood tests appear normal. Correcting iron deficiency can significantly reduce or even eliminate RLS symptoms in a substantial portion of patients.

What to Test

The 2025 AASM guidelines recommend checking:

Serum ferritin: Target level for RLS patients is 75 mcg/L or higher (Note: standard lab "normal" ranges start at 12-30 mcg/L, which is insufficient for RLS management)
Transferrin saturation (TSAT): Should be above 20%
Complete iron panel: Serum iron and total iron-binding capacity (TIBC)

Iron Replacement Options

Oral iron supplementation:

Typically ferrous sulfate 325 mg (65 mg elemental iron) taken every other day on an empty stomach
Take with vitamin C to enhance absorption
Avoid taking with calcium, coffee, or tea (they reduce absorption)
May take 3-6 months to adequately raise ferritin levels
Gastrointestinal side effects (constipation, nausea) are common

Intravenous (IV) iron: The 2025 AASM guidelines provide strong recommendations for IV iron in appropriate patients:

IV ferric carboxymaltose — strong recommendation, moderate certainty of evidence
IV low molecular weight iron dextran — conditional recommendation

IV iron raises ferritin levels much faster than oral supplements (days vs. months) and avoids GI side effects. It is particularly useful when:

Oral iron is not tolerated
Ferritin levels remain low despite oral supplementation
Rapid symptom relief is needed
The patient has absorption issues (gastric bypass, celiac disease, inflammatory bowel disease)

Important Note on Iron Testing

Iron studies should be repeated periodically even after supplementation, as levels can decline over time. If symptoms return, rechecking ferritin should be an early step.

If iron optimization alone does not adequately control symptoms, medication may be needed. The 2025 guidelines make clear distinctions about which medications are recommended and which should be avoided.

Strongly Recommended: Alpha-2-Delta Ligands

These are now the preferred first-line medications for RLS:

Gabapentin

Strong recommendation from the AASM
Typical dose range: 300-1800 mg, taken in the evening
Helps with both the sensory symptoms and sleep disruption
Common side effects: drowsiness, dizziness, weight gain
Not a controlled substance in most states

Gabapentin enacarbil (Horizant)

Strong recommendation from the AASM
An extended-release prodrug of gabapentin specifically FDA-approved for RLS
Typical dose: 600 mg once daily at about 5 PM with food
More consistent absorption than standard gabapentin
Common side effects: drowsiness, dizziness

Pregabalin (Lyrica)

Strong recommendation from the AASM
Typical dose range: 150-450 mg, taken in the evening
May also help with associated anxiety and pain conditions
Common side effects: drowsiness, dizziness, weight gain
Classified as a Schedule V controlled substance

Conditionally Recommended

Dopamine agonists (pramipexole, ropinirole, rotigotine patch):

Now carry only a conditional recommendation — a significant downgrade from prior guidelines
While effective short-term, they carry substantial risk of augmentation (see below)
The guidelines suggest they may be considered when alpha-2-delta ligands are ineffective, not tolerated, or contraindicated
If used, the lowest effective dose should be prescribed

Other medications with conditional recommendations:

Opioids (for refractory cases only, under careful supervision)
Certain other agents may be considered in specific clinical situations

What Is Augmentation?

Augmentation is the most important reason the guidelines shifted away from dopamine agonists. It is a paradoxical worsening of RLS symptoms caused by the very medication used to treat it. Signs include:

Symptoms starting earlier in the day than before treatment
Symptoms spreading to the arms or trunk
Shorter relief from medication doses
Increased symptom intensity overall
Needing higher and higher doses for the same effect

Augmentation occurs in up to 50-70% of patients on long-term dopamine agonist therapy. It can be very difficult to manage once established and often requires slowly tapering off the dopamine agonist while transitioning to a different medication — a process that can temporarily worsen symptoms significantly.

This high augmentation risk is the primary reason the 2025 AASM guidelines now favor alpha-2-delta ligands as first-line treatment.

Lifestyle and Non-Medication Strategies

While not a substitute for medical treatment in moderate to severe RLS, lifestyle measures can provide meaningful relief and complement medication:

Activity and Exercise

Regular moderate exercise (walking, cycling, swimming) can reduce RLS symptoms
Avoid vigorous exercise close to bedtime, which may temporarily worsen symptoms
Stretching, particularly calf and hamstring stretches, before bed may provide relief

Sleep Hygiene

Maintain a consistent sleep schedule
Keep the bedroom cool — some patients find that cooler temperatures help
Avoid prolonged bedrest — get up and move if symptoms are severe

Substances to Avoid

Caffeine — can worsen RLS symptoms. Reduce or eliminate, especially after noon
Alcohol — often worsens symptoms, particularly later in the night
Nicotine — a stimulant that may exacerbate RLS
Antihistamines (diphenhydramine/Benadryl) — commonly worsen RLS and are found in many OTC sleep aids

Medications That May Worsen RLS

Review all current medications with your doctor. The following drug classes are known to potentially trigger or worsen RLS:

SSRI and SNRI antidepressants (sertraline, fluoxetine, venlafaxine, duloxetine)
Older antihistamines (diphenhydramine, doxylamine)
Anti-nausea medications (metoclopramide, prochlorperazine)
Some antipsychotic medications
Lithium

If you are taking one of these medications and have RLS, discuss alternatives with your prescriber. Never stop a prescribed medication without consulting your doctor.

Comfort Measures

Warm baths before bed
Leg massage
Heating pads or ice packs (individual preference varies)
Pneumatic compression devices
Distraction techniques (engaging mental activity can reduce symptom awareness)
Weighted blankets (some patients report benefit, though evidence is limited)

Treatment of Periodic Limb Movement Disorder (PLMD)

The 2025 AASM guidelines also address PLMD specifically:

PLMD is diagnosed when periodic limb movements during sleep cause significant sleep disruption or daytime impairment, and other sleep disorders (particularly RLS and sleep apnea) have been ruled out
Treatment follows a similar approach: iron optimization first, then medications if needed
Dopamine agonists received a conditional recommendation for PLMD
The diagnosis of PLMD requires a sleep study (polysomnography)

Special Situations

RLS During Pregnancy

Affects up to 25-30% of pregnant women, especially in the third trimester
Iron and folate deficiency should be assessed and treated
Most medications used for RLS are not recommended during pregnancy
Symptoms typically resolve after delivery
Non-medication strategies are the primary approach during pregnancy

RLS in Children

RLS can occur in children but is often misdiagnosed as "growing pains" or ADHD
The IRLSSG diagnostic criteria apply, though children may describe symptoms differently
Iron deficiency is especially common and should be assessed first
Treatment decisions should involve a pediatric sleep specialist

RLS in Kidney Disease

Very common in end-stage renal disease (up to 25-50% of dialysis patients)
Iron deficiency is frequent and should be aggressively treated
Some medications require dose adjustment for kidney function
Kidney transplantation often improves RLS symptoms

When Current Treatment Isn't Working

Talk to your sleep provider if:

Symptoms persist despite iron optimization and medication
You are experiencing signs of augmentation (symptoms earlier in the day, spreading to arms, worsening intensity)
Side effects from medication are intolerable
You are currently on a dopamine agonist and want to discuss transitioning to newer recommended therapies
Your symptoms have changed significantly

RLS management sometimes requires adjustments over time. The 2025 guidelines provide a clear framework, but treatment should be individualized to your specific situation.

Key Takeaways

Check iron first: All RLS patients should have ferritin tested. Target ferritin of 75 mcg/L or higher
Iron therapy is foundational: IV iron receives a strong recommendation for appropriate patients
Alpha-2-delta ligands (gabapentin, pregabalin) are now the preferred first-line medications — a major shift from prior guidelines
Dopamine agonists are no longer first-line due to high augmentation risk (50-70% of long-term users)
Avoid known triggers: Caffeine, alcohol, antihistamines, and certain antidepressants can worsen RLS
Lifestyle measures help: Exercise, stretching, sleep hygiene, and avoiding aggravating substances complement medical treatment
Treatment is evolving: If you were previously treated with older approaches, discuss the 2025 guidelines with your provider

Sources